BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Misremembering might actually be a sign your memory is working optimally - 2January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- 3Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- 410 Work Valuable chances to Assist with supporting Your Advanced degree
- 5Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- Manual for Tracking down the Mysterious Cascades in China
- Polish law aimed at lowering petrol prices takes effect
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- Google to Use Natural Gas to Power Massive Data Center in Texas
- Iranian rockets hit Tel Aviv area, injuring six
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- How will the universe end?
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
